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Abstract
Background: The enteric glia network may be involved in the pathogenesis of inflammatory bowel disease (IBD).
Enteric glia cells (EGCs) are the major source of glial-derived neurotrophic factor (GDNF), which regulates apoptosis
of enterocytes. The aim of the study was to determine the distribution of EGCs and GDNF during gut inflammation
and to elucidate a possible diminished enteric glia network in IBD.
Methods: The expression of glial fibrillary acidic protein (GFAP) in colonic biopsies of patients with IBD, controls
and patients with infectious colitis was detected by immunohistochemistry and Western blot. Tissue GDNF levels
were measured by ELISA.
Results: The expression of GFAP and GDNF in the mucosal plexus is highly increased in the inflamed colon of
patients with ulcerative colitis (UC) and infectious colitis. Although the GDNF and GFAP content are increased in
Crohn’s disease (CD), it is significantly less. Additionally the non-inflamed colon of CD patients showed a reduced
GFAP and no GDNF expression compared to controls and the non-inflamed colon of UC patients.
Conclusions: GFAP and GDNF as signs of activated EGCs are increased in the inflamed mucosa of patients with
UC and infectious colitis, which underline an unspecific role of EGC in the regulation of intestinal inflammation.
The reduced GFAP and GDNF content in the colon of CD patients suggest a diminished EGC network in this
disease. This might be a part of the pathophysiological puzzle of CD.
Background
Chronic inflammatory bowel disease (IBD) is most com-
monly categorized into Crohn’s disease (CD) and ulcera-
tive colitis (UC) and afflicts primarily the distal small
and large intestine [1]. At present, there is no definite
cure for these diseases and although the etiology of IBD
remains unknown there are some new insights into its
pathophysiology. Both CD and UC are characterized by
a significant increase of proinflammatory cytokines in
the gut, which trigger and support the inflammatory
processes [2]. Several lines of evidence implicate glial
fibrillary acidic protein (GFAP)-positive enteric glia cells
(EGC) in regulating the inflammatory response in the
gut as well as the integrity of the gut epithelium [3-7].
Genetic ablation of EGCs in mice induced fatal hemor-
rhagic jejuno-ileitis with histopathological changes clo-
sely resembling changes described in human CD [7,8].
Destruction of EGC by auto-immune mechanisms was
shown to induce gut inflammation [9]. EGC processes
are in close proximity to gut epithelial cells and these
cells secrete several mediators implicated in mucosa bar-
rier function. EGCs are producers of transforming
growth factor b (TGF- b) that promote intestinal barrier
function [10]. Recently it was shown that nitric oxide
metabolite S-nitrosogluthatione (GSNO), a novel potent
inducer of intestinal barrier function in human colon
[11] is secreted by EGCs. Furthermore we could show
that EGCs secrete glial-derived neurotrophic factor
(GDNF) whose production is increased during intestinal
inflammation and could act to protect intestinal epithe-
lial cells from cytokine-induced apoptosis [12-14].
It is postulated that EGC populations and its media-
tors are perturbed prior to the clinical onset of intestinal
inflammation [15]. It remains elusive, if CD [9] and/or
UC are indeed characterized by a decreased EGC net-
work and if these changes mark the onset of intestinal
inflammation in IBD.
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ker for EGCs in the inflamed and non-inflamed intes-
tines of patients with CD and UC in comparison to
controls and patients with infectious colitis and postu-
late a diminished EGC network with reduced GDNF
content in the intestines of patients with CD.
Methods
Human tissue
The 101 patients enrolled in the study gave their
informed consent and the study was approved by the
ethical committee of the University of Ulm, which is
leaded by Prof. Dr. U. Brückner. The diagnosis of CD
and UC was established by using usual criteria [16].
Inflamed and non-inflamed colonic biopsies were taken
from 35 patients with CD (15 female/20 male; mean age
31 years; range 21 to 48 years) and from 30 patients
with UC (12 female/18 male; mean age 34 years; range
24 to 52 years). 15 patients with CD were in clinical
remission (Crohn’s Disease Activity Index CDAI < 150)
and 20 patients showed clinically a mild flare (CDAI >
150). 10 patients with UC were in remission defined by
a Colitis Activity Index (CAI) of 0, whereas the other 20
patients suffered from a flare, CAI > 4. Biopsies were
taken during routine ileocolonoscopy only of the left-
sided colonic parts, descending colon and sigmoid. The
definition of non-inflamed or inflamed tissue was
depending on Endoscopic activity using the Simple
Endoscopic Score. (SES-CD) [17]. A SES-CD of 0,
meaning no signs of active inflammation in a colonic
segment defined “non-inflamed”. Five biopsies of a
defined inflamed or non-inflamed colonic segment (des-
cending colon or sigmoid) were taken for analysis.
The mean duration of CD was 6.5 years and the
mean duration of UC was 4.5 years. No patients with
CD or UC received biologics. 10 CD patients were
treated with azathioprine, one patient with 6-MP and 3
patients with budesonide. 8 patients with UC were
treated with azathioprine and 14 patients with mesala-
mine. The other patients were not treated at the time
of study and had only less clinical signs of activity.
As controls healthy colonic biopsies were taken from
26 patients, which underwent a routine screening colono-
scopy (11 female/15 male; mean age 53 years; range 48 to
57 years). Colonic biopsies of 10 patients with infectious
colitis (Clostridium difficile) served as controls for the
inflamed intestines (7 female/3 male; mean age 68 years;
range 59-74 years). Tissue GFAP levels were measured in
a blinded fashion in patients by Western blot analysis
and enzyme-linked immunoabsorbent assay (ELISA).
Indirect immunofluorescence
Tissue-biopsies were deparaffinized and permeabilized
with PBS/0.3% Triton X100.S l i d e sw e r eb l o c k e dw i t h
1% bovine serum (Sigma) in PBS. Antibodies against
GFAP (Pharmingen, San Diego, USA, mouse) and
GDNF (R&D Systems, Wiesbaden, Germany, goat) were
used at dilutions of (1:100) and incubated overnight at
4°C. After washing in PBS/0,1% Tween 20, the slides
were incubated with the appropriate secondary antibo-
dies: cy3 coupled goat anti-mouse IgG (DPC Biermann,
Bad Nauheim, Germany) and Alexa 488 coupled rabbit
anti-goat IgG (Sigma). Dilutions of the secondary anti-
bodies were 1:800. After washing in PBS, slides were
embedded in glycerol gelatine. Control labelling was
performed with omission of the first antibodies to
ensure that there was no unspecific labelling of cells.
Tissue-biopsies were analyzed using a Leica confocal
laser-scanning microscope. Single optical sections were
recorded under conditions, which exclude cross-activa-
tion of the individual signal channels.
Histological analysis
Every Immunolabelled biopsies of 35 CD, 30 UC, 10
infectious colitis patients or 26 control persons were
used for evaluating the expression of GFAP and GDNF
in EGCs.
Western blot analysis
Proteins were extracted from three pooled biopsies in
100 μl of lysis buffer (1% Triton X-100, 150 mM NaCl,
2 0m M ,T r i s - H C Lp H7 . 5 ,2m ME D T A ,1×p r o t e a s e
inhibitor cocktail) for 30 min at 4°C, followed by centri-
fugation for 10 min at 12,000 r.p.m. at 4°C.
All protein samples were normalized to the total pro-
tein content (Bradford reagent; Bio-Rad Laboratories,
Hercules, CA, USA), and comparable loading, as well as
protein transfer after blotting, was confirmed through
detection of Actin as internal control. Protein was
loaded on a 10% SDS gel, separated and blotted. After
blocking with 5% skim milk, primary antibody (glial
fibrillary acidic protein (GFAP) Pharmingen, San Diego,
USA, mouse) was incubated overnight at 4°C. Mem-
branes were washed twice with TBS-T, incubated with
secondary antibody (anti-mouse HRP (1:5000; Dako)),
followed by subsequent washing steps and visualized
with ECL (Amersham Biosciences, Freiburg, Germany).
Western blot bands were analysed by scanning densito-
metry. Multiple exposures of each blot were used to
obtain grey scale images and the GFAP (Pharmingen)
immunoreactive bands were quantified with the Quantity
One Analysis program from Bio-Rad. The data presented
in the figures are expressed as x-fold above controls.
Enzyme-linked immunoabsorbent assay (ELISA)
of colonic tissue
GDNF levels in colonic tissue of patients and controls
were assayed using an ELISA of Promega as described
von Boyen et al. BMC Gastroenterology 2011, 11:3
http://www.biomedcentral.com/1471-230X/11/3
Page 3 of 8before (14). The detection limit of this assay was about
30 pg/ml for GDNF.
Data analysis
All data given in the text and figures are expressed as
mean values ±SEM. The data were analyzed using non-
parametric two-tailed Mann-Whitney U test with p≤0.05
considered as an indicator of significance.
Results
GFAP and GDNF is increased in gut inflammation
EGCs in gut biopsies were identified by immunocyto-
chemical labelling of GFAP and GDNF, which reveals
the enteric glia structures of the mucosal plexus. In the
inflamed intestines of patients with UC a high increase
of both GFAP-positive EGCs and GDNF was seen (Fig-
ure 1A-C) in comparison to control (Figure 1P-R). The
overlay demonstrates the GDNF expression of GFAP-
positive EGCs.
The non-inflamed gut biopsies of UC patients seemed
to be characterized by a more dense enteric glia network
(Figure 1D-F) than controls (Figure 1P-R), but signifi-
cantly less than the inflamed sections (Figure 1A-C).
Patients with colitis Crohn also had an increase in
GFAP and GDNF expression in inflamed colonic biop-
sies (Figure 1G-H), but less impressive than patients
with UC (Figure 1A-C). Colonic parts without inflam-
mation in patients with colitis Crohn (Figure 1J-L)
showed a reduced labelling of GFAP and no expression
of GDNF in comparison to non-inflamed gut structures
of patients with UC (Figure 1D-F).
The biopsies of patients with infectious colitis (Clostri-
dium difficile) was characterized by a impressive
increase of GFAP- and GDNF-positive structures (Figure
1M-Q) similar to the inflamed gut biopsies of patients
with UC (Figure 1A-C).
The biopsies (Figure 1A-R) revealed, that the GFAP-
positive EGCs, which highly express GDNF, are posi-
tioned in the mucosal plexus in close vicinity to the
mucosal epithelium.
(Semi-)Quantification of GFAP expression in the
inflamed intestines
Western blot analysis of extracts from colonic biopsies
of controls revealed a weak basal expression of GFAP
(Figure 2A). However, in the inflamed colon of
patients with UC GFAP expression was upregulated 4-
fold above control levels (Figure 2A). Low basal
expression levels of GFAP were detected in non-
inflamed colonic tissue of UC patients. Although an
increased GFAP content was observed in the inflamed
gut tissue of CD patients, it was less than in biopsies
of UC patients. The non-inflamed intestines of CD
patients were characterized by a low GFAP expression,
which was less than controls or in the non-inflamed
gut tissue of patients with UC.
The GFAP expression of the inflamed intestines in
patients with infectious colitis showed nearly the same
impressive GFAP content, abo u t4 - f o l di nc o m p a r i s o n
to control, like gut inflammation in patients with UC
(Figure 2A). An exemplarily Western-blot of colonic
biopsies is shown in Figure. 3.
Increased levels of GDNF in the inflamed gut
In the gut of control persons we found a basal expres-
sion of GDNF (89 ± 32 pg/ml). In the inflamed colon of
IBD patients a significant increase of GDNF content was
observed as illustrated in Figure 2B. A 2-fold upregula-
tion of GDNF protein was detected in non-inflamed
c o l o n i ct i s s u eo fU Cp a t i e n t s( 1 9 0±6 6p g / m l ) .T h e
highest increase of GDNF content could be observed in
the inflamed colon of patients suffering from UC (812 ±
138 pg/ml, p < 0.05), and in patients suffering from
infectious colitis (775 ± 93 pg/ml, p > 0.05).
Although the GDNF was upregulated in the inflamed
gut tissues of CD (335 ± 86 pg/ml), it was statistically less
than in UC patients or in infectious disease (p < 0.05).
The non-inflamed tissue of CD patients demonstrate no
GDNF expression by ELISA (<30 pg/ml), which is signifi-
cantly less than control (p < 0.05) (Figure 2B).
Discussion
CD and UC are characterized by an inflammation of the
intestines, which is accompanied with an extensive
release of proinflammatory cytokines [2]. Recent studies
with cultured S100-positive EGCs revealed an induction
of GFAP expression upon cytokines stimulation [13].
However, the number and distribution of GFAP-positive
EGCs in the inflamed and non-inflamed gut of IBD
patients is controversially discussed and only few data
exist on EGCs in the intestines of IBD patients and dur-
ing gut inflammation [9,14]. Here we determined the
distribution of GFAP-positive EGCs and GDNF in the
inflamed and non-inflamed colon of patients with CD,
UC and infectious colitis.
It is speculated that the enteric nervous system (ENS)
is disturbed in chronic inflammation of the gut [3-9].
Previous data showed an increase of GDNF and GFAP
in sections of patients with CD [14]. Our data demon-
strate, that in the inflamed tissue of patients with UC,
b o t h ,G F A P - p o s i t i v eE G C sa n dG D N Fi sa l s oh i g h l y
increased. As the same is observed in the colon biopsies
of patients suffering from infectious colitis, increased
EGCs secreting GDNF might be not a specific phenom-
enon in IBD, but a general reaction of the mucosal ENS
during gut inflammation.
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double immunolabelled with anti GFAP (A,D,G,J,M,P red) and anti-GDNF (B,E,H,K,N,Q green) antibodies and were analyzed by optical
sectioning using a confocal microscope. The dotted ovals indicate the position of epithelial crypts. Both antigens, GFAP (A) and GDNF (B) can
be detected highly in the intestinal wall of the inflamed colon of UC (A,B)-, infectious colitis (M,N)- and to a smaller extent in CD patients (G,H).
The merged images (C,I,O) reveal an almost complete overlap of both immunoreactivities (yellow). Only few GFAP-positive cells (G) display no
GDNF immunoreactivity (H, I) in the non-inflamed colon of CD patients and the control section (P-R), whereas in non-inflamed tissue of UC
patients GFAP-positive EGCs (D) showing slight GDNF expression (E). GFAP-positive EGCs (A,D,G,J,M,P) are positioned in the mucosal plexus in
close vicinity to the epithelium of the colon. Scale bars, 50 μm.
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tion is increased in the inflamed mucosa of CD and that
GDNF acts anti-apoptotic on intestinal epithelial cells
[12,14]. EGCs serve as the main source of mucosal
GDNF and a loss of EGCs [14], lead to a severe inflam-
mation of the gut by a disruption of the mucosal barrier
[18]. A defect EGC network is postulated for CD. This is
underlined by our findings. Although GDNF - anti-apop-
tic agent for epithelial cells- and GFAP is increased in the
inflamed gut of CD, it is significantly less than in the
inflamed intestines of UC patients or patients with infec-
tious colitis. Interestingly, in the non-inflamed tissue of
CD patients, GDNF could be not detected in the range of
the used ELISA (>30 pg/ml), as sign of a reduced GDNF
secretion, maybe caused by a disturbed EGC network.
The diminished GFAP expression in the non-inflamed
and in the inflamed tissue of CD patients might be an
indicator for a chronic dysfunction of EGCs.
As loss of EGCs lead to gut inflammation [7,8] and
several animal models demonstrate EGCs and their
Figure 2 Tissue GFAP levels in clinical biopsies. (A). Western blot analysis of tissue extracts from controls, inflamed UC (UC-I), non-inflamed
UC (UC-N), inflamed CD (CD-I), non-inflamed CD (CD-N) and infectious colitis (IC) using anti-GFAP antibodies. (A) shows the densitometric
analysis of GFAP expression in the colon tissues of the different clinical groups; the data are expressed as x-fold above control. * indicates a
significant increase of GFAP in tissue samples of inflamed intestines compared with control (p < 0.05). ** indicates a significant reduction of
GFAP in CD-N compared to control and UC-N (P < 0.05). (B) GDNF concentrations (pg/ml) in the colon biopsies of the different clinical groups.
*Significantly different from control (P < 0.05). **Significantly different from UC-I and IC (P < 0.05).
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tools for maintaining the integrity of the gut [9-11,14], it
might be speculated that the reduced EGC network of
CD patients is part of the pathophysiological puzzle in
this disease.
It is imaginable that innate defects of the enteric glia
network lead to a leaky mucosal barrier, which influ-
ences the adaptive immune system [6,19]. This might be
a speculative process in developing CD. Otherwise a
chronic transmural inflammation like in CD might lead
to a diminished enteric glia network, which reacts insuf-
ficient during mucosal inflammation. The loss of EGCs
and their protecting substances like GDNF, TGF- b and
GSNO lead to the failure of the mucosal barrier and
exaggerate intestinal inflammation. The inflammation in
UC is localized in the luminal parts of the intestines,
e.g. in the mucosa. Thus, there might be no relevant
defects in the enteric glia network of UC patients, which
is underlined by our results with a high secretion of
GDNF during gut inflammation.
Conclusions
In conclusion our data show that the protective feed
back loop of GFAP-positive EGCs, secreting GDNF to
regenerate an intact barrier function is not specific for
IBD but an unspecific reaction of the enteric glia
network during gut inflammation. Furthermore the
intestines of CD patients are characterized by a reduced
number of EGCs with a diminished secretion of GDNF
during inflammation and might be a part of the patho-
physiological processes in CD. This underlines that CD
and UC are different diseases.
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